课题基金 / 基金详情

Targeting Leukemic Stem Cells

Targeting Leukemic Stem Cells
靶向白血病干细胞
批准号:
8113184
负责人:
DANIEL G TENEN
金额:
$41.93万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-25 至 2013-07-31

项目摘要

项目成果

DANIEL G TENEN的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):尽管近年来我们对涉及血液器官和其他组织的疾病的基因异常的理解取得了显著进展,但通过基因治疗方法在靶细胞中引入或操纵基因表达的能力仍然有限。尽管许多强大的病毒载体已被开发并用于实验和人体系统,但许多问题,特别是安全性,表明需要开发用于基因治疗的非病毒载体。最近的发现也表明,有必要针对正常造血干细胞(HSC)和白血病干细胞(LSC),这些细胞具有自我更新和在给定组织中产生所有细胞类型的潜力,白血病干细胞(LSC)是一种癌细胞亚群,赋予恶性白血病克隆的自我更新特性。正常的人HSC和大多数LSC表达干细胞抗原CD34,本研究将利用这一表面标记的特异性,以及一种新的小鼠模型,在小鼠HSC中表达人CD34抗原。因此,该项目的长期目标是开发针对正常和白血病干细胞的新型非病毒基因治疗方法。为了实现这些目标,我们提出以下具体目标:(1)测试人CD34抗体介导的siRNA在人CD34细胞系中的传递;(2)在小鼠体内模型中检测人CD34抗体介导的siRNA;(3)检测人CD34抗体介导的BCR/ABL或SALL4的沉默是否有效
英文摘要
DESCRIPTION (provided by applicant): Although advances in our understanding of gene abnormalities in diseases involving blood organs and other tissues has been remarkable in recent years, the ability to introduce or manipulate expression of genes in target cells through gene therapy methods has been limited. Although a number of powerful viral vectors have been developed and utilized in both experimental and human systems, a number of issues, particularly safety, have demonstrated the need to develop non-viral based vectors for gene therapy. Recent discoveries have also demonstrated that it is essential to target normal hematopoietic stem cells (HSC), cells which have the potential to both self-renew and to give rise to all cell types in a given tissue, as well as leukemic stem cells (LSC), a subpopulation of cancer cells which confer the self-renewal properties of the malignant leukemic clone. Normal human HSC, and a majority of LSC, express the stem cell antigen CD34, and this proposal will utilize the specificity of this surface marker, as well as a novel murine model in which murine HSC express the human CD34 antigen. Therefore, the long range goals of this project are to develop novel non-viral gene therapy methods targeting normal and leukemic stem cells. In order to accomplish these goals, we propose the following Specific Aims: (1) to test human CD34 antibody mediated siRNA delivery in human CD34 cell lines; (2) to test human CD34 antibody mediated siRNA in murine models in vivo; and (3) to test whether human CD34 antibody mediated silencing of BCR/ABL or SALL4 will inhibit proliferation and leukemia-initiating ability of human primary myeloid LSCs. Accomplishment of these goals will set the stage for clinical trials, as well as lead to development of therapies directed against other oncogenes as well as altering stem cell gene expression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 3 - Transcriptional and epigenetic heterogeneity of stem/progenitor cells
  • 批准号:
    10641542
  • 项目类别:
  • 资助金额:
    $51.63万
  • 财政年份:
    2017
  • 负责人:
    DANIEL G TENEN
  • 依托单位:
Noncoding RNA-DNMT1 interactions in hematopoiesis
Mechanisms of regulation by RNA in acute myeloid leukemia
Noncoding RNA-DNMT1 interactions in hematopoiesis
海外基金